Effect of almonertinib on the proliferation, invasion, and migration in non-small cell lung cancer cells.
10.11817/j.issn.1672-7347.2021.201009
- Author:
Yuhan ZHANG
1
,
2
;
Yaoshuai ZHANG
1
,
3
;
Wenwen NIU
1
,
3
;
Xianming GE
1
,
3
;
Xian LI
1
,
3
;
Fangtian FAN
1
,
3
;
Shanshan LI
1
,
3
;
Hao LIU
1
,
4
Author Information
1. School of Pharmacy, Bengbu Medical College
2. Anhui Provincial Engineering Technology Research Center of Biochemical Pharmaceuticals, Bengbu Anhui 233030, China. zyh9787@foxmail.com.
3. Anhui Provincial Engineering Technology Research Center of Biochemical Pharmaceuticals, Bengbu Anhui 233030, China.
4. Anhui Provincial Engineering Technology Research Center of Biochemical Pharmaceuticals, Bengbu Anhui 233030, China. liuhao6886@foxmail.com.
- Publication Type:Journal Article
- Keywords:
almonertinib;
epidermal growth factor receptor tyrosine kinase inhibitor;
epithelial mesenchymal transformation;
invasion;
non-small cell lung cancer;
proliferation
- MeSH:
Acrylamides;
Animals;
Apoptosis;
Carcinoma, Non-Small-Cell Lung/drug therapy*;
Cell Line, Tumor;
Cell Proliferation;
Drug Resistance, Neoplasm;
ErbB Receptors/genetics*;
Humans;
Indoles;
Lung Neoplasms;
Mice;
Mice, Nude;
Mutation;
Protein Kinase Inhibitors/pharmacology*;
Pyrimidines
- From:
Journal of Central South University(Medical Sciences)
2021;46(10):1045-1053
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:Lung cancer is one of the most common malignant tumors in the world, and its lethality ranks the first among many malignant tumors. For non-small cell lung cancer (NSCLC) patients, due to the high mortality rate, the overall 5-year survival rate is less than 15%. When NSCLC undergoes local invasion, the 5-year survival rate is only 20%, and it is even lower when distant metastasis occurs up to 4%. Almonertinib is an innovative drug independently researched and developed by China with independent intellectual property rights. As an epidermal growth factor receptor tyrosine kinase inhibitor, almonertinib is mainly used for locally advanced or metastatic NSCLC patients with epidermal growth factor receptor (EGFR) T790M mutation. This study aims to investigate the effects of almonertinib on the proliferation, invasion and migration of NSCLC cells in vitro.
METHODS:NSCLC cells H1975 and PC-9 were cultured in vitro. The effects of almonertinib on the proliferation, apoptosis, invasion, and migration of H1975 and PC-9 cells were detected by CCK-8 assay, apoptotic assay and Transwell assay. The expression of invasion and migration related proteins was detected by Western blotting.
RESULTS:The CCK-8 experiment showed that almonertinib inhibited the proliferation of H1975 and PC-9 cells in a time- and dose-dependent manner. The IC
CONCLUSIONS:Almonertinib can inhibit the proliferation, invasion, and migration of NSCLCH1975 and PC-9 cells in vitro and vivo, and promote the apoptosis of H1975 and PC-9 cells. The underlying mechanism may be related to the inhibition of tumor cell epithelial mesenchymal transformation and metalloproteinase expression.
